Skip to main content
Top
Published in: Virology Journal 1/2010

Open Access 01-12-2010 | Research

Keratin 18 phosphorylation as a progression marker of chronic hepatitis B

Authors: Ying Shi, Shihui Sun, Yali Liu, Junfeng Li, Tong Zhang, Hao Wu, Xinyue Chen, Dexi Chen, Yusen Zhou

Published in: Virology Journal | Issue 1/2010

Login to get access

Abstract

Background

The intermediate filament proteins keratins 18 (K18) and 8 (K8) polymerize to form the cytoskeletal network in the mature hepatocytes. It has been shown that the phosphorylation of K18 at two serine residues, 33 and 52, correlates with the progression of hepatitis C, but little is known of chronic hepatitis B (CHB). In this study, we examined K18 phosphorylation in relation to CHB.

Results

Site-specific phosphorylation of K18 was determined in livers of twelve healthy donors, and non-cirrhosis (n = 40) and cirrhosis (n = 21) patients. On average, progressively higher level of Ser52 phosphorylation was observed in non-cirrhotic and cirrhotic livers, while elevated Ser33 phosphorylation was detected in both livers but no significant difference. Progressive increase of Ser33 and Ser52 phosphorylation correlated with the elevation of both histological lesions and enzymatic activities of alanine aminotransferase in non-cirrhotic livers. In the hepatocytes of an inactive HBV carrier, strong signals of Ser33 phosphorylation were co-localized with viral infection, while only basal level of Ser52 phosphorylation was detected in infected cells.

Conclusion

Assuming all obtained data, our data suggest that K18 phosphorylation is a progression marker for CHB.
Appendix
Available only for authorised users
Literature
1.
go back to reference Omary MB, Ku NO, Toivola DM: Keratins, Guardians of the liver. Hepatology 2002, 35: 251-257. 10.1053/jhep.2002.31165PubMedCrossRef Omary MB, Ku NO, Toivola DM: Keratins, Guardians of the liver. Hepatology 2002, 35: 251-257. 10.1053/jhep.2002.31165PubMedCrossRef
2.
go back to reference Coulombe PA, Omary MB: 'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol 2002, 14: 110-122. 10.1016/S0955-0674(01)00301-5PubMedCrossRef Coulombe PA, Omary MB: 'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol 2002, 14: 110-122. 10.1016/S0955-0674(01)00301-5PubMedCrossRef
3.
go back to reference Marceau N, Loranger A, Gilbert S, Daigle N, Champetier S: Keratin mediated resistance to stress and apoptosis in simple epithelial cells in relation to health and disease. Biochem Cel Biol 2001, 79: 543-555. 10.1139/bcb-79-5-543CrossRef Marceau N, Loranger A, Gilbert S, Daigle N, Champetier S: Keratin mediated resistance to stress and apoptosis in simple epithelial cells in relation to health and disease. Biochem Cel Biol 2001, 79: 543-555. 10.1139/bcb-79-5-543CrossRef
4.
go back to reference Gonzalez-Quintela A, Abdulkader I, Campos J, Fernandez-Hernandez L, Lojo S: Serum levels of keratin-18 fragments [tissue polypeptide-specific antigen (TPS)] are correlated with hepatocyte apoptosis in alcoholic hepatitis. Dig Dis Sci 2009, 54: 648-653. 10.1007/s10620-008-0371-2PubMedCrossRef Gonzalez-Quintela A, Abdulkader I, Campos J, Fernandez-Hernandez L, Lojo S: Serum levels of keratin-18 fragments [tissue polypeptide-specific antigen (TPS)] are correlated with hepatocyte apoptosis in alcoholic hepatitis. Dig Dis Sci 2009, 54: 648-653. 10.1007/s10620-008-0371-2PubMedCrossRef
5.
go back to reference Gonzalez-Quintela A, Lojo S, Otero E, Perez LF: Keratin-18 as a marker of steatohepatitis. Hepatology 2006, 44: 27-33. Gonzalez-Quintela A, Lojo S, Otero E, Perez LF: Keratin-18 as a marker of steatohepatitis. Hepatology 2006, 44: 27-33.
6.
go back to reference Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG: Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007, 13: 837-844.PubMedPubMedCentralCrossRef Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, Aker S, Yilmaztepe A, Gurel S, Gulten M, Nak SG: Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007, 13: 837-844.PubMedPubMedCentralCrossRef
7.
go back to reference Simopoulos C, Tsaroucha AK, Asimakopoulos B, Giatromanolaki A, Gavriilidis P, Polychronidis A, Karaiannakis A: Total and caspase-cleaved cytokeratin 18 in chronic cholecystitis: A prospective study. BMC Gastroenterol 2008, 8: 14-18. 10.1186/1471-230X-8-14PubMedPubMedCentralCrossRef Simopoulos C, Tsaroucha AK, Asimakopoulos B, Giatromanolaki A, Gavriilidis P, Polychronidis A, Karaiannakis A: Total and caspase-cleaved cytokeratin 18 in chronic cholecystitis: A prospective study. BMC Gastroenterol 2008, 8: 14-18. 10.1186/1471-230X-8-14PubMedPubMedCentralCrossRef
8.
go back to reference Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, Manolakopoulos S, Tiniakos DG, Giannousis I, Manesis EK, Archimandritis AJ: Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut 2008, 57: 500-506. 10.1136/gut.2007.123943PubMedCrossRef Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, Manolakopoulos S, Tiniakos DG, Giannousis I, Manesis EK, Archimandritis AJ: Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut 2008, 57: 500-506. 10.1136/gut.2007.123943PubMedCrossRef
9.
go back to reference Caulin C, Ware CF, Magin TM, Oshima RG: Keratin-dependent, epithelial resistance to tumor necrosis factor-induced apoptosis. J Cell Biol 2000, 149: 17-22. 10.1083/jcb.149.1.17PubMedPubMedCentralCrossRef Caulin C, Ware CF, Magin TM, Oshima RG: Keratin-dependent, epithelial resistance to tumor necrosis factor-induced apoptosis. J Cell Biol 2000, 149: 17-22. 10.1083/jcb.149.1.17PubMedPubMedCentralCrossRef
10.
go back to reference Gilbert S, Loranger A, Daigle N, Marceau N: Simple epithelium keratins 8 and 18 provide resistance to Fas-mediated apoptosis. The protection occurs through a receptor-targeting modulation. J Cell Biol 2001, 154: 763-773. 10.1083/jcb.200102130PubMedPubMedCentralCrossRef Gilbert S, Loranger A, Daigle N, Marceau N: Simple epithelium keratins 8 and 18 provide resistance to Fas-mediated apoptosis. The protection occurs through a receptor-targeting modulation. J Cell Biol 2001, 154: 763-773. 10.1083/jcb.200102130PubMedPubMedCentralCrossRef
11.
go back to reference Ku NO, Soetikno RM, Omary MB: Keratin mutation in transgenic mice predisposes to Fas but not TNF-induced apoptosis and massive liver injury. Hepatology 2003, 37: 1006-1014. 10.1053/jhep.2003.50181PubMedCrossRef Ku NO, Soetikno RM, Omary MB: Keratin mutation in transgenic mice predisposes to Fas but not TNF-induced apoptosis and massive liver injury. Hepatology 2003, 37: 1006-1014. 10.1053/jhep.2003.50181PubMedCrossRef
12.
go back to reference Inada H, Izawa I, Nishizawa M, Fujita E, Kiyono T, Takahashi T, Momoi T, Inagaki M: Keratin attenuates tumor necrosis factor-induced cytotoxicity through association with TRADD. J Cell Biol 2001, 155: 415-426. 10.1083/jcb.200103078PubMedPubMedCentralCrossRef Inada H, Izawa I, Nishizawa M, Fujita E, Kiyono T, Takahashi T, Momoi T, Inagaki M: Keratin attenuates tumor necrosis factor-induced cytotoxicity through association with TRADD. J Cell Biol 2001, 155: 415-426. 10.1083/jcb.200103078PubMedPubMedCentralCrossRef
13.
go back to reference Ku NO, Michie S, Resurreccion EZ, Broome RL, Omary MB: Keratin binding to 14-3-3 proteins modulates keratin filaments and hepatocyte mitotic progression. Proc Natl Acad Sci USA 2002, 99: 4373-4378. 10.1073/pnas.072624299PubMedPubMedCentralCrossRef Ku NO, Michie S, Resurreccion EZ, Broome RL, Omary MB: Keratin binding to 14-3-3 proteins modulates keratin filaments and hepatocyte mitotic progression. Proc Natl Acad Sci USA 2002, 99: 4373-4378. 10.1073/pnas.072624299PubMedPubMedCentralCrossRef
14.
go back to reference Galarneau L, Loranger A, Gilbert S, Marceau N: Keratins modulate hepatic cell adhesion, size and G1/S transition. Exp Cell Res 2007, 313: 179-194. 10.1016/j.yexcr.2006.10.007PubMedCrossRef Galarneau L, Loranger A, Gilbert S, Marceau N: Keratins modulate hepatic cell adhesion, size and G1/S transition. Exp Cell Res 2007, 313: 179-194. 10.1016/j.yexcr.2006.10.007PubMedCrossRef
15.
go back to reference Ku NO, Michie SA, Soetikno RM, Resurreccion EZ, Broome RL, Omary MB: Mutation of a major keratin phosphorylation site predisposes to hepatotoxic injury in transgenic mice. J Cell Biol 1998, 143: 2023-2032. 10.1083/jcb.143.7.2023PubMedPubMedCentralCrossRef Ku NO, Michie SA, Soetikno RM, Resurreccion EZ, Broome RL, Omary MB: Mutation of a major keratin phosphorylation site predisposes to hepatotoxic injury in transgenic mice. J Cell Biol 1998, 143: 2023-2032. 10.1083/jcb.143.7.2023PubMedPubMedCentralCrossRef
16.
go back to reference Omary MB, Ku NO, Tao GZ, Toivola DM, Liao J: 'Heads and tails' of intermediate filament phosphorylation: multiple sites and functional insights. Trends Biochem Sci 2006, 31: 383-394. 10.1016/j.tibs.2006.05.008PubMedCrossRef Omary MB, Ku NO, Tao GZ, Toivola DM, Liao J: 'Heads and tails' of intermediate filament phosphorylation: multiple sites and functional insights. Trends Biochem Sci 2006, 31: 383-394. 10.1016/j.tibs.2006.05.008PubMedCrossRef
17.
go back to reference Toivola DM, Ku NO, Resurreccion EZ, Nelson DR, Wright TL, Omary MB: Keratin 8 and 18 hyperphosphorylation is a marker of progression of human liver disease. Hepatology 2004, 40: 459-466. 10.1002/hep.20277PubMedCrossRef Toivola DM, Ku NO, Resurreccion EZ, Nelson DR, Wright TL, Omary MB: Keratin 8 and 18 hyperphosphorylation is a marker of progression of human liver disease. Hepatology 2004, 40: 459-466. 10.1002/hep.20277PubMedCrossRef
18.
go back to reference Stumptner C, Omary MB, Fickert P, Denk H, Zatloukal K: Hepatocyte cytokeratins are hyperphosphorylated at multiple sites in human alcoholic hepatitis and in a mallory body mouse model. Am J Pathol 2000, 156: 77-90.PubMedPubMedCentralCrossRef Stumptner C, Omary MB, Fickert P, Denk H, Zatloukal K: Hepatocyte cytokeratins are hyperphosphorylated at multiple sites in human alcoholic hepatitis and in a mallory body mouse model. Am J Pathol 2000, 156: 77-90.PubMedPubMedCentralCrossRef
19.
go back to reference Denk H, Stumptner C, Zatloukal K: Mallory bodies revisited. J Hepatol 2000, 32: 689-702. 10.1016/S0168-8278(00)80233-0PubMedCrossRef Denk H, Stumptner C, Zatloukal K: Mallory bodies revisited. J Hepatol 2000, 32: 689-702. 10.1016/S0168-8278(00)80233-0PubMedCrossRef
20.
go back to reference Zatloukal K, Stumptner C, Fuchsbichler A, Peter F, Carolin L, Michael T, Helmut D: The keratin cytoskeleton in liver diseases. J Pathol 2004, 204: 367-376. 10.1002/path.1649PubMedCrossRef Zatloukal K, Stumptner C, Fuchsbichler A, Peter F, Carolin L, Michael T, Helmut D: The keratin cytoskeleton in liver diseases. J Pathol 2004, 204: 367-376. 10.1002/path.1649PubMedCrossRef
21.
go back to reference Fickert P, Trauner M, Fuchsbichler A, Stumptner C, Zatloukal K, Denk H: Mallory body formation in primary biliary cirrhosis is associated with increased amounts and abnormal phosphorylation and ubiquitination of cytokeratins. J Hepatol 2003, 38: 387-394. 10.1016/S0168-8278(02)00439-7PubMedCrossRef Fickert P, Trauner M, Fuchsbichler A, Stumptner C, Zatloukal K, Denk H: Mallory body formation in primary biliary cirrhosis is associated with increased amounts and abnormal phosphorylation and ubiquitination of cytokeratins. J Hepatol 2003, 38: 387-394. 10.1016/S0168-8278(02)00439-7PubMedCrossRef
22.
go back to reference Fausther M, Villeneuve L, Cadrin M: Heat shock protein 70 expression, keratin phosphorylation and Mallory body formation in hepatocytes from griseofulvin-intoxicated mice. Comp Hepatol 2004, 3: 5-21. 10.1186/1476-5926-3-5PubMedPubMedCentralCrossRef Fausther M, Villeneuve L, Cadrin M: Heat shock protein 70 expression, keratin phosphorylation and Mallory body formation in hepatocytes from griseofulvin-intoxicated mice. Comp Hepatol 2004, 3: 5-21. 10.1186/1476-5926-3-5PubMedPubMedCentralCrossRef
23.
go back to reference Koziel MJ: Cellular immune responses against hepatitis C virus. Clin Infect Dis 2005,41(Suppl 1):25-31. 10.1086/429492CrossRef Koziel MJ: Cellular immune responses against hepatitis C virus. Clin Infect Dis 2005,41(Suppl 1):25-31. 10.1086/429492CrossRef
24.
go back to reference Isabel F: Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009, 15: 513-520. 10.3748/wjg.15.513CrossRef Isabel F: Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009, 15: 513-520. 10.3748/wjg.15.513CrossRef
25.
go back to reference Schuchmann M, Galle PR: Apoptosis in liver disease. Eur J Gastroenterol Hepatol 2001, 13: 785-790. 10.1097/00042737-200107000-00005PubMedCrossRef Schuchmann M, Galle PR: Apoptosis in liver disease. Eur J Gastroenterol Hepatol 2001, 13: 785-790. 10.1097/00042737-200107000-00005PubMedCrossRef
26.
go back to reference Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC: TP53 and liver carcinogenesis. Hum Mutat 2003, 21: 201-216. 10.1002/humu.10176PubMedCrossRef Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC: TP53 and liver carcinogenesis. Hum Mutat 2003, 21: 201-216. 10.1002/humu.10176PubMedCrossRef
27.
go back to reference Chinese Medical Association: Infectious and Parasitic Disease, and Hepatology Branches, Prevention and treatment of viral hepatitis. Chin J Hepatol 2000, 8: 324-329. Chinese Medical Association: Infectious and Parasitic Disease, and Hepatology Branches, Prevention and treatment of viral hepatitis. Chin J Hepatol 2000, 8: 324-329.
28.
go back to reference Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, Phillips MJ, Portmannl BG, Paulsen H, Scheuer PJ, Schmid M, Thaler H: Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22: 696-699. 10.1016/0168-8278(95)80226-6PubMedCrossRef Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, Phillips MJ, Portmannl BG, Paulsen H, Scheuer PJ, Schmid M, Thaler H: Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22: 696-699. 10.1016/0168-8278(95)80226-6PubMedCrossRef
29.
go back to reference Ku NO, Liao J, Chou CF, Omary MB: Implications of intermediate filament protein phosphorylation. Cancer Metastasis Rev 1996, 15: 429-444. 10.1007/BF00054011PubMedCrossRef Ku NO, Liao J, Chou CF, Omary MB: Implications of intermediate filament protein phosphorylation. Cancer Metastasis Rev 1996, 15: 429-444. 10.1007/BF00054011PubMedCrossRef
30.
go back to reference Bert S, Mieke H, Wendy K, Maartje B, Stephan M, Mathie PGL, Marius N, Viveka B, Peter B, Bertil B, Lane EB, Omary MB, Hans J, Frans CSR: Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 2004, 297: 11-26. 10.1016/j.yexcr.2004.02.019CrossRef Bert S, Mieke H, Wendy K, Maartje B, Stephan M, Mathie PGL, Marius N, Viveka B, Peter B, Bertil B, Lane EB, Omary MB, Hans J, Frans CSR: Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 2004, 297: 11-26. 10.1016/j.yexcr.2004.02.019CrossRef
Metadata
Title
Keratin 18 phosphorylation as a progression marker of chronic hepatitis B
Authors
Ying Shi
Shihui Sun
Yali Liu
Junfeng Li
Tong Zhang
Hao Wu
Xinyue Chen
Dexi Chen
Yusen Zhou
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2010
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-7-70

Other articles of this Issue 1/2010

Virology Journal 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.